335 Interim results of a randomized trial of 1.5μG/ KG vs. 3.0 μG/KG pegylated interferon alfa 2-B PEG-intron(R) (PEG) plus ribavirin (RBV) for naïve chronic hepatitis C patients and 3.0μG/KG PEG plus RBV for non-responders (NR) and relapsers (R) to previous therapy. (The target trial)

24 Weeks Treatment with Pegylated Interferon Alfa Plus Ribavirin May Be Possible in Genotype 1 Chronic Hepatitis C Patients with Rapid Virological Response Who Have Low Pretreatment Viremia

Korean Journal of Gastroenterology ◽

10.4166/kjg.2010.56.1.33 ◽

2010 ◽

Vol 56 (1) ◽

pp. 33 ◽

Cited By ~ 3

Author(s):

Sung Soo Moon ◽

Hyoun Gu Kang ◽

Jeong Ah Seo ◽

Eun Uk Jung ◽

Sang Heon Lee ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Virological Response ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Rapid Virological Response ◽

Genotype 1 ◽

838 Pegylated Interferon Alfa, Nitazoxanide, Telapravir, Ribavirin, in Genotype 1 Undergoing Prior Experienced Chronic Hepatitis C Patients-a Randomized Placebo Control Clinical Pilot Trial (I N T R I G U E C) Interim

Gastroenterology ◽

10.1016/s0016-5085(12)63615-4 ◽

2012 ◽

Vol 142 (5) ◽

pp. S-932 ◽

Cited By ~ 1

Author(s):

Patrick Basu ◽

Thankam Nair ◽

Sakina Farhat ◽

Sajith Foustin ◽

Lynn P. Ang ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pilot Trial ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Placebo Control ◽

Genotype 1 ◽

Pegylated Interferon Alfa, Nitazoxanide, Telaprevir, Ribavirin, in Genotype 1 Undergoing Prior Experienced Chronic Hepatitis C Patients - A Randomized Placebo Control Clinical Pilot Trial (INTRIGUE-C)

The American Journal of Gastroenterology ◽

10.14309/00000434-201210001-00363 ◽

2012 ◽

Vol 107 ◽

pp. S154

Author(s):

Patrick Basu ◽

N. Shah ◽

S. Farhat ◽

R. Siriki ◽

Md Rahman ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pilot Trial ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Placebo Control ◽

Genotype 1 ◽

FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program

10.1016/j.jhep.2010.06.038 ◽

2011 ◽

Vol 54 (2) ◽

pp. 227-235 ◽

Cited By ~ 14

Author(s):

Thierry Poynard ◽

Mona Munteanu ◽

Massimo Colombo ◽

Jordi Bruix ◽

Eugene Schiff ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Independent Predictor ◽

Pegylated Interferon ◽

Virologic Response ◽

Interferon Alfa ◽

492 A phase II, placebo-controlled study of merimepodib (XV-497), in combination with pegylated interferon-alfa, and ribavirin in patients with chronic hepatitis C non-responsive to previous therapy with interferon-alfa and ribavirin

10.1016/s0168-8278(04)90492-8 ◽

2004 ◽

Vol 40 ◽

pp. 145 ◽

Cited By ~ 5

Author(s):

P. Marcellin ◽

Y. Horsmans ◽

F. Nevens ◽

J.D. Grange ◽

J.P. Bronowicki ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Phase Ii ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Controlled Study ◽

Previous Therapy ◽

Pegylated Interferon Alfa

469 ITPA GENE VARIANT PROTECTS AGAINST TREATMENT-INDUCED ANEMIA AND IMPROVES VIRAL CLEARANCE BY PEGYLATED INTERFERON-ALFA AND RIBAVIRIN THERAPY IN CHRONIC HEPATITIS C PATIENTS

10.1016/s0168-8278(11)60471-6 ◽

2011 ◽

Vol 54 ◽

pp. S191-S192

Author(s):

N. Sakamoto ◽

Y. Tanaka ◽

M. Nakagawa ◽

H. Yatsuhashi ◽

S. Nishiguchi ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Viral Clearance ◽

Gene Variant ◽

1102 THE COST-EFFECTIVENESS OF TELAPREVIR (TVR) IN COMBINATION WITH PEGYLATED INTERFERON-ALFA AND RIBAVIRIN (PR) FOR THE TREATMENT OF GENOTYPE 1 CHRONIC HEPATITIS C PATIENTS

10.1016/s0168-8278(12)61114-3 ◽

2012 ◽

Vol 56 ◽

pp. S434 ◽

Cited By ~ 3

Author(s):

S. Curtis ◽

S. Cure ◽

S. Gavart ◽

L. Dearden ◽

J. Fleischmann ◽

...

Keyword(s):

Chronic Hepatitis ◽

Cost Effectiveness ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Genotype 1 ◽

The Cost ◽

Low dose erythropoietin-beta improves anemia and maintains ribavirin dose in chronic hepatitis C patients receiving combination therapy with ribavirin plus pegylated interferon Alfa-2b

Hepatology Research ◽

10.1111/j.1872-034x.2009.00489.x ◽

2009 ◽

Vol 39 (6) ◽

pp. 539-545 ◽

Cited By ~ 8

Author(s):

Kuo-Chih Tseng ◽

Li-Hsuan Chen ◽

Chi-Yi Chen ◽

Ting-Tsung Chang ◽

An-Liang Chou ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Combination Therapy ◽

Chronic Hepatitis C ◽

Low Dose ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Oxidative stress and antioxidant defense in patients with chronic hepatitis C patients before and after pegylated interferon alfa-2b plus ribavirin therapy

Journal of Translational Medicine ◽

10.1186/1479-5876-4-25 ◽

2006 ◽

Vol 4 (1) ◽

Cited By ~ 64

Author(s):

Görenek Levent ◽

Acar Ali ◽

Aydın Ahmet ◽

Eyigun Can Polat ◽

Çetinkaya Aytaç ◽

...

Keyword(s):

Oxidative Stress ◽

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Antioxidant Defense ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Before And After ◽

Corrigendum to: “FibroTest is an independent predictor of virologic response in chronic hepatitis C patients retreated with pegylated interferon alfa-2b and ribavirin in the EPIC3 program” [J Hepatol 2011;54:227–235]

10.1016/j.jhep.2013.07.006 ◽

2013 ◽

Vol 59 (4) ◽

pp. 914

Author(s):

Thierry Poynard ◽

Mona Munteanu ◽

Massimo Colombo ◽

Jordi Bruix ◽

Eugene Schiff ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C ◽

Chronic Hepatitis C ◽

Independent Predictor ◽

Pegylated Interferon ◽

Virologic Response ◽

Interferon Alfa ◽